Enjoy complimentary customisation on priority with our Enterprise License!
The injection pen market size is forecast to increase by USD 25.51 billion at a CAGR of 8.13% between 2023 and 2028. The market is experiencing significant growth due to the rising prevalence of chronic diseases such as diabetes, cancer, and osteoporosis. The demand for injection pens is particularly high in the treatment of diabetes, where insulin pens hold the majority share. The affordability and simplicity of use of disposable injection pens have made them a preferred choice among patients. However, safety concerns, including side-effects from pen needles and insulin dosage errors, remain challenges in the market. The aging population is another key factor driving market growth, as older adults are more likely to have chronic conditions requiring regular medication administration. Overall, the market is expected to continue its upward trajectory, with continued innovation in safety features and affordability being key focus areas for market participants.
The injector pen market is witnessing significant growth due to the rising prevalence of chronic diseases such as diabetes, osteoporosis, cardiovascular disease (CVD), multiple sclerosis, and cancer. Regulatory approvals and government support for the use of injector pens in disease management have boosted market growth. Technological advancements, including needle-free devices and biosimilars, are also driving market expansion. However, poor reimbursement scenarios in some regions and needle anxiety and needle-stick injuries remain challenges. Developing regions, particularly in Asia Pacific, offer significant growth opportunities due to increasing awareness and rising healthcare expenditures. Insurance companies and governments are collaborating to increase access to these medical devices, which will further fuel market growth. The market is expected to grow steadily, with insulin, drug cartridges, needles, syringes, plungers, and injector pens being key components. The market is also witnessing increasing adoption in the treatment of chronic diseases, including diabetes, CVD, and cancer.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The growth hormone segment is estimated to witness significant growth during the forecast period. Injection pens play a crucial role in the delivery of biosimilars, particularly insulin for the treatment of chronic diseases such as diabetes and cancer, as well as human growth hormone for conditions like growth deficiencies in the geriatric population. These medical devices consist of a needle, syringe, plunger, drug cartridge, and insulin delivery system. The increasing prevalence of diabetes, with an estimated 463 million people affected according to the International Diabetes Federation, and the growing number of individuals requiring insulin therapy, are significant factors driving the demand for injection pens.
Insurance companies and governments are actively promoting the use of these devices to manage the rising healthcare costs and improve patient convenience. CVS Caremark, a leading pharmacy benefits manager, has reported an increase in the usage of insulin pens due to their ease of use and portability. The market for injection pens is expected to grow substantially due to the increasing prevalence of chronic diseases, the aging population, and the availability of biosimilars.
Get a glance at the market share of various segments Request Free Sample
The growth hormone segment accounted for USD 11.57 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is experiencing steady growth, driven by the presence of major players based in the US and Canada. These companies, including those specializing in biosimilars, have a significant impact on the market due to their large customer base and direct sales channels. Diabetic populations, particularly those suffering from chronic conditions like Type 1 and Type 2 diabetes, and the geriatric population, are key consumers of insulin delivery devices such as injection pens. The International Diabetes Federation reports that over 34 million Americans have diabetes, making the US a significant market for insulin pens. Additionally, the rising prevalence of cancer and other chronic diseases further increases the demand for these medical devices.
Moreover, insurance companies and governments also play a crucial role in driving market growth by covering the costs of insulin pens and associated supplies for their customers. The market in North America includes various components such as needles, syringes, plungers, drug cartridges, and insulin, making it a comprehensive medical device sector.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising prevalence of chronic diseases is the key driver of the market. The market is experiencing significant growth due to the increasing prevalence of chronic diseases such as diabetes, multiple sclerosis, cancer, and cardiovascular diseases (CVD). Regulatory approvals and government support for the use of injection pens in treating these conditions are driving market expansion. Technological advancements, including needle-free devices, are addressing concerns related to needle anxiety and needle-stick injuries, thereby enhancing patient compliance.
Further, the market is witnessing strong growth in emerging markets, particularly in developing regions, where the burden of chronic diseases is rising. Despite the potential benefits, poor reimbursement scenarios in some regions may pose challenges to market growth. The market is expected to continue its upward trajectory, providing opportunities for key players to innovate and expand their offerings.
A significant rise in demand for insulin pens is the upcoming trend in the market. Chronic diseases such as diabetes, osteoporosis, multiple sclerosis, and cardiovascular disease require effective and convenient therapy for optimal patient management. Insulin, a proven treatment for diabetes, has significantly improved patient outcomes by enabling better glycemic control. This reduction in health complications includes risks of retinopathy, neuropathy, nephropathy, and cardiovascular disease. However, despite the known benefits, insulin therapy faces challenges due to patient unwillingness and fear of injections, pain during administration, hypoglycemia, and insufficient education. Regulatory approvals and reimbursement policies, coupled with government support, are crucial in addressing these challenges.
Further, technological advancements, such as needle-free devices and injector pens, aim to enhance patient compliance and mitigate concerns related to needle anxiety and needle-stick injuries. In developing regions, these advancements hold significant potential in improving healthcare access and patient outcomes. Emerging markets present opportunities for growth in the injector pen market, as the demand for convenient and safe therapy solutions continues to increase.
Side-effects of injection pens is a key challenge affecting the market growth. Injection pens have gained significant traction in the healthcare industry due to their convenience and ease of use, particularly for managing chronic diseases such as diabetes, osteoporosis, and cardiovascular disease (CVD). Regulatory approvals and government support have accelerated the market growth of injection pens in both developed and emerging markets. Technological advancements have led to the development of needle-free devices, addressing concerns related to needle anxiety and needle-stick injuries. However, poor reimbursement scenarios in some regions may hinder market growth.
For instance, multiple sclerosis patients using injection pens face the risk of severe side effects, including hepatic injury and anaphylaxis. These risks may discourage patient compliance and encourage the exploration of alternative treatment methods. Despite these challenges, the market is expected to continue expanding, driven by the increasing prevalence of chronic diseases and the ongoing development of innovative technologies.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The injector pen market is witnessing significant growth due to the increasing prevalence of chronic diseases such as diabetes, cardiovascular disease (CVD), osteoporosis, multiple sclerosis, and cancer in the geriatric population. Regulatory approvals and government support for the use of injector pens in home-care settings and hospitals & clinics are driving the market growth. Technological advancements, including automated injection pens with Bluetooth technology, needle-free devices, and insulin pens with disposable needles, are enhancing the patient experience and improving treatment adherence. However, poor reimbursement scenarios and affordability remain major challenges in developing regions and emerging economies. Needle anxiety and needle-stick injuries are also concerns for patients.
Further, the market is segmented into disposable and reusable injection pens, with disposable pens holding the majority share due to their simplicity of use and affordability. The market is expected to grow steadily during the forecast period, with major players focusing on safety, precision, and convenience in medication delivery. The increasing prevalence of chronic diseases, particularly diabetes, in wealthy nations and developing countries, is fueling the demand for injector pens. The aging population and government initiatives to improve healthcare infrastructure are also contributing to the market growth. Insulin, growth hormones, and drugs for fertility are some of the major applications of injector pens.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
172 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.13% |
|
Market growth 2024-2028 |
USD 25.51 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
7.54 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 44% |
|
Key countries |
US, Canada, China, Germany, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AstraZeneca Plc, Becton Dickinson and Co., Biocon Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gan and Lee Pharmaceuticals Co. Ltd., Gerresheimer AG, GlaxoSmithKline Plc, Harro Hofliger GmbH, Haselmeier GmbH, Jiangsu Delfu medical device Co. Ltd., Merck KGaA, Novartis AG, Novo Nordisk AS, Owen Mumford Ltd., Pfizer Inc., Sanofi, Solteam Electronics Co LTD., Viatris Inc., and Ypsomed Holding AG |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
